Doxepin incorporated into a dermatologic cream: an assessment of both doxepin antipruritic action and doxepin action as an inhibitor of papules, in allergen and histamine-caused pruritus
Doxepin incorporated into a dermatologic cream: an assessment of both doxepin antipruritic action and doxepin action as an inhibitor of papules, in allergen and histamine-caused pruritus
G. Keskin, A. Inal, R. Ali Sari, A. S ¸engül, M. S¸ahin, M. Turgay
Read
4731
Timeswas read the article
81
Total PDF
4650
Total HTML
Article information
ISSN: 03010546Original language: English
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2099 7 | 539 | 0 | 539 |
| 2025 12 | 59 | 0 | 59 |
| 2025 11 | 270 | 0 | 270 |
| 2025 10 | 189 | 0 | 189 |
| 2025 9 | 165 | 0 | 165 |
| 2025 8 | 168 | 0 | 168 |
| 2025 7 | 134 | 0 | 134 |
| 2025 6 | 111 | 0 | 111 |
| 2025 5 | 157 | 0 | 157 |
| 2025 4 | 107 | 0 | 107 |
| 2025 3 | 101 | 0 | 101 |
| 2025 2 | 66 | 0 | 66 |
| 2025 1 | 60 | 0 | 60 |
| 2024 12 | 60 | 0 | 60 |
| 2024 11 | 62 | 0 | 62 |
| 2024 10 | 41 | 0 | 41 |
| 2024 9 | 43 | 0 | 43 |
| 2024 8 | 26 | 0 | 26 |
| 2024 7 | 43 | 0 | 43 |
| 2024 6 | 43 | 0 | 43 |
| 2024 5 | 29 | 0 | 29 |
| 2024 4 | 39 | 0 | 39 |
| 2024 3 | 31 | 0 | 31 |
| 2024 2 | 30 | 0 | 30 |
| 2024 1 | 74 | 1 | 75 |
| 2023 12 | 41 | 5 | 46 |
| 2023 11 | 37 | 5 | 42 |
| 2023 10 | 89 | 7 | 96 |
| 2023 9 | 45 | 1 | 46 |
| 2023 8 | 53 | 3 | 56 |
| 2023 7 | 53 | 0 | 53 |
| 2023 6 | 53 | 0 | 53 |
| 2023 5 | 48 | 1 | 49 |
| 2023 4 | 12 | 0 | 12 |
| 2023 3 | 37 | 0 | 37 |
| 2023 2 | 14 | 0 | 14 |
| 2023 1 | 39 | 0 | 39 |
| 2022 12 | 20 | 0 | 20 |
| 2022 11 | 32 | 0 | 32 |
| 2022 10 | 27 | 0 | 27 |
| 2022 9 | 16 | 0 | 16 |
| 2022 8 | 19 | 0 | 19 |
| 2022 7 | 19 | 1 | 20 |
| 2022 6 | 16 | 0 | 16 |
| 2022 5 | 31 | 0 | 31 |
| 2022 4 | 27 | 0 | 27 |
| 2022 3 | 20 | 0 | 20 |
| 2022 2 | 15 | 0 | 15 |
| 2022 1 | 19 | 0 | 19 |
| 2021 12 | 14 | 0 | 14 |
| 2021 11 | 18 | 0 | 18 |
| 2021 10 | 12 | 0 | 12 |
| 2021 9 | 13 | 1 | 14 |
| 2021 8 | 8 | 1 | 9 |
| 2021 7 | 12 | 0 | 12 |
| 2021 6 | 10 | 0 | 10 |
| 2021 5 | 13 | 4 | 17 |
| 2021 4 | 34 | 8 | 42 |
| 2021 3 | 59 | 0 | 59 |
| 2021 2 | 26 | 0 | 26 |
| 2021 1 | 5 | 0 | 5 |
| 2018 3 | 5 | 0 | 5 |
| 2018 2 | 12 | 0 | 12 |
| 2018 1 | 4 | 0 | 4 |
| 2017 12 | 14 | 0 | 14 |
| 2017 11 | 13 | 0 | 13 |
| 2017 10 | 6 | 0 | 6 |
| 2017 9 | 13 | 0 | 13 |
| 2017 8 | 10 | 0 | 10 |
| 2017 7 | 17 | 0 | 17 |
| 2017 6 | 14 | 16 | 30 |
| 2017 5 | 12 | 11 | 23 |
| 2017 4 | 17 | 13 | 30 |
| 2017 3 | 11 | 0 | 11 |
| 2017 2 | 12 | 0 | 12 |
| 2017 1 | 4 | 0 | 4 |
| 2016 12 | 13 | 3 | 16 |
| 2016 11 | 8 | 0 | 8 |
| 2016 10 | 13 | 0 | 13 |
| 2016 9 | 11 | 0 | 11 |
| 2016 8 | 10 | 0 | 10 |
| 2016 7 | 9 | 0 | 9 |
| 2016 6 | 13 | 0 | 13 |
| 2016 5 | 6 | 0 | 6 |
| 2016 4 | 12 | 0 | 12 |
| 2016 3 | 11 | 0 | 11 |
| 2016 2 | 14 | 0 | 14 |
| 2016 1 | 16 | 0 | 16 |
| 2015 12 | 9 | 0 | 9 |
| 2015 11 | 10 | 0 | 10 |
| 2015 10 | 17 | 0 | 17 |
| 2015 9 | 14 | 0 | 14 |
| 2015 8 | 15 | 0 | 15 |
| 2015 7 | 8 | 0 | 8 |
| 2015 6 | 8 | 0 | 8 |
| 2015 5 | 17 | 0 | 17 |
| 2015 4 | 13 | 0 | 13 |
| 2015 3 | 10 | 0 | 10 |
| 2015 2 | 20 | 0 | 20 |
| 2015 1 | 37 | 0 | 37 |
| 2014 12 | 29 | 0 | 29 |
| 2014 11 | 12 | 0 | 12 |
| 2014 10 | 19 | 0 | 19 |
| 2014 9 | 26 | 0 | 26 |
| 2014 8 | 17 | 0 | 17 |
| 2014 7 | 16 | 0 | 16 |
| 2014 6 | 10 | 0 | 10 |
| 2014 5 | 10 | 0 | 10 |
| 2014 4 | 11 | 0 | 11 |
| 2014 3 | 31 | 0 | 31 |
| 2014 2 | 31 | 0 | 31 |
| 2014 1 | 28 | 0 | 28 |
| 2013 12 | 24 | 0 | 24 |
| 2013 11 | 26 | 0 | 26 |
| 2013 10 | 32 | 0 | 32 |
| 2013 9 | 36 | 0 | 36 |
| 2013 8 | 50 | 0 | 50 |
| 2013 7 | 31 | 0 | 31 |
| 2013 6 | 18 | 0 | 18 |
| 2013 5 | 18 | 0 | 18 |
| 2013 4 | 9 | 0 | 9 |
| 2013 3 | 9 | 0 | 9 |
| 2012 11 | 1 | 0 | 1 |
Show all
